Variants in hormone biosynthesis genes and risk of endometrial cancer

Sara H. Olson; Irene Orlow; Sharon Bayuga; Camelia Sima; Elisa V. Bandera; Katherine Pulick; Shameka Faulkner; Diana Tommasi; Daniel Egan; Pampa Roy; Homer Wilcox; Ali Asya; Ippolito Modica; Haider Asad; Robert Soslow; Ann G. Zauber

doi:10.1007/s10552-008-9160-7

Variants in hormone biosynthesis genes and risk of endometrial cancer

Sara H. Olson, Irene Orlow, Sharon Bayuga, Camelia Sima, Elisa V. Bandera, Katherine Pulick, Shameka Faulkner, Diana Tommasi, Daniel Egan, Pampa Roy, Homer Wilcox, Ali Asya, Ippolito Modica, Haider Asad, Robert Soslow, Ann G. Zauber

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Abstract

We investigated the risk associated with variants in three genes involved in estrogen biosynthesis, CYP11A1, CYP17A1, and CYP19A1, in the population-based case-control study of Estrogen, Diet, Genetics, and Endometrial Cancer. This study was conducted in New Jersey in 2001-2006 with 417 cases and 402 controls. For CYP11A1, there was no association between the number of [TTTTA]_n repeats (D15S520) and risk. For CYP17A1, risk was somewhat lower among women with the C/C genotype at T-34C (rs743572) (adjusted OR = 0.65, 95% CI 0.41-1.02). For CYP19A1, risk was lower among women homozygous for the 3-bp deletion (rs11575899) in exon 4 (adjusted OR = 0.44, 95% CI 0.26-0.76), while the number of [TTTA]_n repeats was not significantly related to risk: the adjusted OR for n = 7/7 repeats versus n > 7/>7 repeats was 0.81 (95% CI 0.54-1.23). In stratified analyses, results for CYP19A1 were stronger among women with higher (≥27.4) body mass index: for the homozygous deletion, OR = 0.30 (95% CI 0.15-0.62); for the n = 7/7 genotype, OR = 0.49 (95% CI 0.26-0.93). The interaction between the n = 7/7 genotype and BMI was statistically significant (p = 0.01). The insertion/deletion variant in CYP19A1 appears to be related to risk of endometrial cancer; risk associated with variants in this gene may vary according to BMI.

Original language	English
Pages (from-to)	955-963
Number of pages	9
Journal	Cancer Causes and Control
Volume	19
Issue number	9
DOIs	https://doi.org/10.1007/s10552-008-9160-7
State	Published - Nov 2008
Externally published	Yes

Keywords

CYP11A1
CYP17A1
CYP19A1
Endometrial cancer
Epidemiology

Access to Document

10.1007/s10552-008-9160-7

Cite this

@article{00c980a569aa4f3cbe6824c8609e704b,

title = "Variants in hormone biosynthesis genes and risk of endometrial cancer",

abstract = "We investigated the risk associated with variants in three genes involved in estrogen biosynthesis, CYP11A1, CYP17A1, and CYP19A1, in the population-based case-control study of Estrogen, Diet, Genetics, and Endometrial Cancer. This study was conducted in New Jersey in 2001-2006 with 417 cases and 402 controls. For CYP11A1, there was no association between the number of [TTTTA]n repeats (D15S520) and risk. For CYP17A1, risk was somewhat lower among women with the C/C genotype at T-34C (rs743572) (adjusted OR = 0.65, 95% CI 0.41-1.02). For CYP19A1, risk was lower among women homozygous for the 3-bp deletion (rs11575899) in exon 4 (adjusted OR = 0.44, 95% CI 0.26-0.76), while the number of [TTTA]n repeats was not significantly related to risk: the adjusted OR for n = 7/7 repeats versus n > 7/>7 repeats was 0.81 (95% CI 0.54-1.23). In stratified analyses, results for CYP19A1 were stronger among women with higher (≥27.4) body mass index: for the homozygous deletion, OR = 0.30 (95% CI 0.15-0.62); for the n = 7/7 genotype, OR = 0.49 (95% CI 0.26-0.93). The interaction between the n = 7/7 genotype and BMI was statistically significant (p = 0.01). The insertion/deletion variant in CYP19A1 appears to be related to risk of endometrial cancer; risk associated with variants in this gene may vary according to BMI.",

keywords = "CYP11A1, CYP17A1, CYP19A1, Endometrial cancer, Epidemiology",

author = "Olson, {Sara H.} and Irene Orlow and Sharon Bayuga and Camelia Sima and Bandera, {Elisa V.} and Katherine Pulick and Shameka Faulkner and Diana Tommasi and Daniel Egan and Pampa Roy and Homer Wilcox and Ali Asya and Ippolito Modica and Haider Asad and Robert Soslow and Zauber, {Ann G.}",

note = "Funding Information: Acknowledgments We thank the interviewers, students, and staff who worked on this study: Silvia Brendel, Nora Geraghty, Dina Gifkins, June Kittredge, Sharon Lojun, Elinor Miller, Louise Salant, Mathilde Saxon, Michelle Sriprasert, Elizabeth Ward, Doreen Wass, Melony Williams, Kay Yoon; and New Jersey Department of Health and Senior Services personnel Tara Blando, Stacey Izzard, Joan Kay, Betsy Kohler, Kevin Masterson, Helen Weiss. Financial support: National Cancer Institute grants R01CA83918 (S. Olson) and K07CA095666 (E. Bandera).",

year = "2008",

month = nov,

doi = "10.1007/s10552-008-9160-7",

language = "English",

volume = "19",

pages = "955--963",

journal = "Cancer Causes and Control",

issn = "0957-5243",

publisher = "Springer Netherlands",

number = "9",

}

TY - JOUR

T1 - Variants in hormone biosynthesis genes and risk of endometrial cancer

AU - Olson, Sara H.

AU - Orlow, Irene

AU - Bayuga, Sharon

AU - Sima, Camelia

AU - Bandera, Elisa V.

AU - Pulick, Katherine

AU - Faulkner, Shameka

AU - Tommasi, Diana

AU - Egan, Daniel

AU - Roy, Pampa

AU - Wilcox, Homer

AU - Asya, Ali

AU - Modica, Ippolito

AU - Asad, Haider

AU - Soslow, Robert

AU - Zauber, Ann G.

N1 - Funding Information: Acknowledgments We thank the interviewers, students, and staff who worked on this study: Silvia Brendel, Nora Geraghty, Dina Gifkins, June Kittredge, Sharon Lojun, Elinor Miller, Louise Salant, Mathilde Saxon, Michelle Sriprasert, Elizabeth Ward, Doreen Wass, Melony Williams, Kay Yoon; and New Jersey Department of Health and Senior Services personnel Tara Blando, Stacey Izzard, Joan Kay, Betsy Kohler, Kevin Masterson, Helen Weiss. Financial support: National Cancer Institute grants R01CA83918 (S. Olson) and K07CA095666 (E. Bandera).

PY - 2008/11

Y1 - 2008/11

N2 - We investigated the risk associated with variants in three genes involved in estrogen biosynthesis, CYP11A1, CYP17A1, and CYP19A1, in the population-based case-control study of Estrogen, Diet, Genetics, and Endometrial Cancer. This study was conducted in New Jersey in 2001-2006 with 417 cases and 402 controls. For CYP11A1, there was no association between the number of [TTTTA]n repeats (D15S520) and risk. For CYP17A1, risk was somewhat lower among women with the C/C genotype at T-34C (rs743572) (adjusted OR = 0.65, 95% CI 0.41-1.02). For CYP19A1, risk was lower among women homozygous for the 3-bp deletion (rs11575899) in exon 4 (adjusted OR = 0.44, 95% CI 0.26-0.76), while the number of [TTTA]n repeats was not significantly related to risk: the adjusted OR for n = 7/7 repeats versus n > 7/>7 repeats was 0.81 (95% CI 0.54-1.23). In stratified analyses, results for CYP19A1 were stronger among women with higher (≥27.4) body mass index: for the homozygous deletion, OR = 0.30 (95% CI 0.15-0.62); for the n = 7/7 genotype, OR = 0.49 (95% CI 0.26-0.93). The interaction between the n = 7/7 genotype and BMI was statistically significant (p = 0.01). The insertion/deletion variant in CYP19A1 appears to be related to risk of endometrial cancer; risk associated with variants in this gene may vary according to BMI.

AB - We investigated the risk associated with variants in three genes involved in estrogen biosynthesis, CYP11A1, CYP17A1, and CYP19A1, in the population-based case-control study of Estrogen, Diet, Genetics, and Endometrial Cancer. This study was conducted in New Jersey in 2001-2006 with 417 cases and 402 controls. For CYP11A1, there was no association between the number of [TTTTA]n repeats (D15S520) and risk. For CYP17A1, risk was somewhat lower among women with the C/C genotype at T-34C (rs743572) (adjusted OR = 0.65, 95% CI 0.41-1.02). For CYP19A1, risk was lower among women homozygous for the 3-bp deletion (rs11575899) in exon 4 (adjusted OR = 0.44, 95% CI 0.26-0.76), while the number of [TTTA]n repeats was not significantly related to risk: the adjusted OR for n = 7/7 repeats versus n > 7/>7 repeats was 0.81 (95% CI 0.54-1.23). In stratified analyses, results for CYP19A1 were stronger among women with higher (≥27.4) body mass index: for the homozygous deletion, OR = 0.30 (95% CI 0.15-0.62); for the n = 7/7 genotype, OR = 0.49 (95% CI 0.26-0.93). The interaction between the n = 7/7 genotype and BMI was statistically significant (p = 0.01). The insertion/deletion variant in CYP19A1 appears to be related to risk of endometrial cancer; risk associated with variants in this gene may vary according to BMI.

KW - CYP11A1

KW - CYP17A1

KW - CYP19A1

KW - Endometrial cancer

KW - Epidemiology

UR - http://www.scopus.com/inward/record.url?scp=52549131350&partnerID=8YFLogxK

U2 - 10.1007/s10552-008-9160-7

DO - 10.1007/s10552-008-9160-7

M3 - Article

C2 - 18437511

AN - SCOPUS:52549131350

VL - 19

SP - 955

EP - 963

JO - Cancer Causes and Control

JF - Cancer Causes and Control

SN - 0957-5243

IS - 9

ER -

Variants in hormone biosynthesis genes and risk of endometrial cancer

Abstract

Keywords

Access to Document

Fingerprint

Cite this